amantadine has been researched along with alpha-aminopyridine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hohlfeld, R; Zimmermann, C | 1 |
| Waubant, E | 1 |
| Hamann, M; Lange, N; Lemm, C; Richter, A; Sander, SE | 1 |
1 review(s) available for amantadine and alpha-aminopyridine
| Article | Year |
|---|---|
['Fatigue' in multiple sclerosis].
Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis; Pemoline; Potassium Channel Blockers; Severity of Illness Index | 1999 |
2 other study(ies) available for amantadine and alpha-aminopyridine
| Article | Year |
|---|---|
[Therapeutic indications for managing symptoms: fatigue].
Topics: Amantadine; Aminopyridines; Double-Blind Method; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Retigabine, a K(V)7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Amantadine; Aminopyridines; Animals; Anticonvulsants; Antiparkinson Agents; Behavior, Animal; Carbamates; Dyskinesia, Drug-Induced; Female; Motor Activity; Oxidopamine; Phenylenediamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 2012 |